MissionIRNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Reports on Clinical Data Showing Lead Compound Combined with GLP-1 Agonist Enhances Cognition

 Annovis Bio (NYSE: ANVS), a late-stage, clinical-drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer’s disease (“AD”) and Parkinson’s disease (“PD”), is reporting preclinical data regarding its lead compound, buntanetap. According to the announcement, the results show the synergistic effect of buntanetap when combined with the glucagon-like peptide 1 (“GLP-1”) agonist dulaglutide (Trulicity[R]) in a mouse model of Alzheimer’s disease.

Based on data gathered in 2018 showing that buntanetap fully restored memory, learning and synaptic potentiation in an Alzheimer’s mouse model, Annovis recently studied whether buntanetap combined with the GLP-1 agonist dulaglutide produced a synergistic effect in the same animal model. Calling the results “compelling,” the company reported that while buntanetap alone restored cognitive function to 100%, the two compounds together enhanced cognitive function beyond levels seen in healthy controls.

“We are excited to see that buntanetap significantly amplifies the effects of dulaglutide on memory and learning, with a 6- to 10-fold increase in efficacy,” said Annovis Bio founder, president and CEO Maria Maccecchini, PhD, in the press release. “This synergy is particularly important for enhancing treatment outcomes while minimizing potential side effects. As the field of Alzheimer’s research shifts towards combination therapies, we believe our approach holds great promise for offering more effective treatment options for patients.”

To view the full press release, visit https://ibn.fm/jiQu5

About Annovis Bio Inc.

Annovis Bio is headquartered in Malvern, Pennsylvania, and is dedicated to addressing neurodegeneration in diseases such as Alzheimer’s disease (“AD”) and Parkinson’s disease (“PD”). The company’s innovative approach targets multiple neurotoxic proteins, aiming to restore brain function and improve the quality of life for patients. For more information about the company, visit www.AnnovisBio.com.

NOTE TO INVESTORS: The latest news and updates relating to ANVS are available in the company’s newsroom at https://ibn.fm/ANVS

About MissionIR

MissionIR (“MIR”) is a specialized communications platform with a focus on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, MIR is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MIR brings its clients unparalleled recognition and brand awareness.

MIR is where breaking news, insightful content and actionable information converge.

For more information, please visit www.MissionIR.com

Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: https://www.MissionIR.com/Disclaimer

MissionIR
Los Angeles, CA
www.MissionIR.com
310.299.1717 Office
Editor@MissionIR.com

MissionIR is powered by IBN

Clene Inc. (NASDAQ: CLNN) Advances Neurodegenerative Disease Treatment with Innovative Nanotherapeutics

 

• Clene is developing a new class of drugs that hold the potential to transform the lives of millions suffering from debilitating conditions such as Amyotrophic Lateral Sclerosis (“ALS”), Multiple Sclerosis (“MS”), and Parkinson’s Disease (“PD”)
• CNM-Au8(R), Clene’s lead drug candidate, is a fundamentally new approach for treating the underlying factors contributing to ALS, MS, and PD, by restoring neuronal health and function
• ALS, the most prevalent adult-onset progressive motor neuron disease, affects approximately 30,000 people in the U.S.

Clene (NASDAQ: CLNN), a pioneering biopharmaceutical company, is making significant strides in the treatment of neurodegenerative diseases through its novel nanotherapeutic platform. With a mission to improve underlying mitochondrial health and protect neuronal function, Clene is developing a new class of drugs that hold the potential to transform the lives of millions suffering from debilitating conditions such as Amyotrophic Lateral Sclerosis (“ALS”), Multiple Sclerosis (“MS”), and Parkinson’s Disease (“PD”).

At the forefront of Clene’s innovations is CNM-Au8, a gold nanocrystal suspension currently in  development. CNM-Au8 is designed to act as a treatment for ALS, MS, and PD by restoring                neuronal health and function. The drug works by increasing cell energy production and utilization, driving critical cellular reactions that promote neuroprotection and remyelination, thereby enhancing neuronal and glial resilience to disease-related stressors.

In a recent Xtalks podcast, Clene discussed the significant developments of CNM-Au8 and its unique technology. CNM-Au8’s mechanism of action involves the conversion of critical energetic metabolites within living cells to produce ATP, the essential energy currency for cellular functions. The gold nanocrystals attract a coating of apolipoproteins from human plasma, facilitating their passage through the blood-brain barrier and into the brain, where they can protect neurons from death and repair damaged neurons by catalyzing energy production (https://ibn.fm/Gvb5o).

CNM-Au8 is being evaluated in multiple clinical trials, including the prestigious Harvard/MGH HEALEY ALS Platform Trial, which targets patients with mid-to-late stage ALS. The drug has also completed the RESCUE-ALS proof-of-concept clinical trial for early symptomatic ALS, and the REPAIR trials, showing promising changes in brain energy metabolites with CNM-Au8 administration. Additionally, CNM-Au8 has completed a clinical trial, VISIONARY-MS, for treating visual pathway deficits in chronic optic neuropathy, demonstrating its potential for remyelination in stable relapsing MS.

With more than 650 estimated years of collective exposure across ALS, MS, and PD participants in CNM-Au8 clinical trials and Expanded Access Protocol (compassionate use) programs, CNM-Au8 has shown a robust safety profile without any observed safety signals. The drug is designed to be used in combination with other agents and has no known drug-drug interactions, making it a versatile option for patients.

ALS, the most prevalent adult-onset progressive motor neuron disease, affects approximately 30,000 people in the U.S. and an estimated 500,000 people worldwide. Clene estimates that global ALS treatment sales will exceed $1 billion annually in the coming years, underscoring the urgent need for viable treatment options.

Founded in 2013 and based in Salt Lake City, Utah, Clene Inc. is at the forefront of developing innovative treatments for neurodegenerative diseases. With research and development, as well as manufacturing operations in Maryland, Clene is committed to transforming the treatment landscape for ALS, MS, PD, and other debilitating conditions through its groundbreaking nanotherapeutic platform.

For more information, visit the company’s website at www.Clene.com.

NOTE TO INVESTORS: The latest news and updates relating to CLNN are available in the company’s newsroom at https://ibn.fm/CLNN

About MissionIR

MissionIR (“MIR”) is a specialized communications platform with a focus on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, MIR is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MIR brings its clients unparalleled recognition and brand awareness.

MIR is where breaking news, insightful content and actionable information converge.

For more information, please visit www.MissionIR.com

Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: https://www.MissionIR.com/Disclaimer

MissionIR
Los Angeles, CA
www.MissionIR.com
310.299.1717 Office
Editor@MissionIR.com

Correlate Energy Corp. (CIPI) Makes Energy Transition an Attainable Option for Climate-conscious Customers

 

• Decentralized energy generation for specific geographic locations is growing in popularity as a solution for customers searching for climate-friendly alternatives
• Environmentally conscious corporations are likewise seeking solutions that will help them meet global sustainability goals and social and governance reporting
• Distributed energy solutions developer Correlate Energy Corp. is helping clients meet the challenges of the modern energy era, focusing on behind-the-meter solar infrastructure improvements, access to financing, and measurable progress in sustainable solutions
• Correlate Energy is using strategic partnerships to boost its ability to provide clients with data-driven responsiveness for decarbonization, site analysis, and design proposal needs

Companies worldwide are working to build environmental, social and governance (“ESG”) initiatives, while meeting the expectations of investors. A recent Deloitte survey indicates that a majority of US companies report progress on sustainability (https://ibn.fm/ZDILd).

At the same time, a recent Forbes column noted the difficulties that global corporations face in meeting deadlines and standards applied under a variety of agreements, ranging from the Corporate Sustainability Due Diligence Directive (“CSDDD”) in Europe to the Securities Exchange Commission’s (“SEC’s”) Climate Related Disclosure Standards in the U.S.

“The transition mandate in the CSDDD is a blessing in disguise for many firms because it will act as the impetus for a standard set of benchmarks for evaluating sustainability risk across supply chains and put some much-needed structure around data collection, reporting and actions,” the report states (https://ibn.fm/6E3ib). “That will, in turn, provide better insights for investors and consumers to evaluate each company’s real stance on sustainability on an apples-to-apples basis.”

Distributed energy solutions company Correlate Energy (OTCQB: CIPI) is making renewable energy measures more accessible for corporations and residential customers alike, increasing the incentive to make the transition to climate-friendly distributed energy systems.

As Correlate Energy develops its own localized clean energy solutions and microgrids, and helps clients figure out the best way to set up their own, it can connect them with sources of financing, manage the construction process, and ensure goals are being met while building reporting transparency in the process.

“Behind the meter solar … has been our focus for a long time, specifically on large commercial and industrial properties,” Correlate’s Solar Energy & Storage Director Jason Loyet said during a March webcast with analytics partner Xendee (https://ibn.fm/CbFKP). “I think a lot of developers and a lot of commercial sales people are getting approached by national portfolios — same with Correlate. We’re at a unique opportunity in the industry.”

Additionally, some utility clients are finding decentralized energy generation an attractive alternative to central grids beset by power outage problems insufficient infrastructure.

For more information, visit the company’s website at www.Correlate.Energy, including the following:

• Breaking Down Barriers To Your ESG Goals While Generating Additional Net Operating Income:  www.correlate.energy/our-process
• Platform Generates New Rent And Operating Income, Allowing You To Meet Your ESG Goals: www.correlate.energy/program

NOTE TO INVESTORS: The latest news and updates relating to CIPI are available in the company’s newsroom at https://ibn.fm/CIPI

About MissionIR

MissionIR (“MIR”) is a specialized communications platform with a focus on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, MIR is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MIR brings its clients unparalleled recognition and brand awareness.

MIR is where breaking news, insightful content and actionable information converge.

For more information, please visit www.MissionIR.com

Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: https://www.MissionIR.com/Disclaimer

MissionIR
Los Angeles, CA
www.MissionIR.com
310.299.1717 Office
Editor@MissionIR.com